Acadia Pharmaceuticals (NASDAQ:ACAD) soars 51% after saying that the results of a Phase III trial of its Pimavanserin drug, plus other data, are enough for the company to file an application for FDA approval. Acadia will not now conduct a confirmatory phase III trial that was due to start this month. Pimavanserin is designed to treat Parkinson's disease psychosis. (PR)
Acadia Pharmaceuticals (NASDAQ:ACAD) soars 51% after saying that the results of a Phase III...
Recommended For You
About ACAD Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ACAD | - | - |
ACADIA Pharmaceuticals Inc. |